Madelynn Whittaker
@mnwhittaker.bsky.social
📤 17
📥 31
📝 5
boston-based scientist editing DNA and occasionally her coffee order
reposted by
Madelynn Whittaker
NEJM.org
5 days ago
Personalized therapies hold tremendous promise but challenge traditional models of drug and biologic development. The
@fda.gov
outlines a path to market entry for products where a randomized trial is not feasible. Learn more:
nej.md/4nUQdcl
0
1
4
reposted by
Madelynn Whittaker
Nature Metabolism
11 days ago
loading . . .
Blood methylome signatures in children exposed to maternal type 1 diabetes are linked to protection against islet autoimmunity
Nature Metabolism, Published online: 06 November 2025; doi:10.1038/s42255-025-01403-wThrough an epigenome-wide blood analysis in children of mothers with or without type 1 diabetes, the authors identify epigenetic modifications of type 1 diabetes susceptibility loci through which maternal type 1 diabetes may protect from islet autoimmunity in offspring.
https://bit.ly/491x0SI
0
2
1
My first-author paper was published today in Nature Biomedical Engineering! Here we describe how incorporating DNA substitutions into various positions of the Cas9 guide RNA protospacer can enhance the precision and performance of adenine base editors. 🧬 ✂️
20 days ago
1
3
0
reposted by
Madelynn Whittaker
Lauren Testa
20 days ago
🧬Proud to share "Improved specificity and efficiency of in vivo adenine base editing therapies with hybrid guide RNAs" my 1st first-author paper of my PhD, co-first-authored with the brilliant Dr.
@mnwhittaker.bsky.social
, is out today in Nature Biomedical Engineering!
www.nature.com/articles/s41...
loading . . .
Improved specificity and efficiency of in vivo adenine base editing therapies with hybrid guide RNAs - Nature Biomedical Engineering
Hybrid gRNAs significantly increase targeted editing in the liver while simultaneously reducing unwanted bystander editing in humanized mouse models.
https://www.nature.com/articles/s41551-025-01545-y
1
3
2
reposted by
Madelynn Whittaker
Nature Biotechnology
4 months ago
Platform solutions for commercial challenges to expanding patient access and making gene editing sustainable
go.nature.com/4kCD1Y3
0
3
6
you reached the end!!
feeds!
log in
